European Commission Gives Clearance for INEOS acquisition of Hydro Polymers
Advertisement
INEOS Capital confirms that it has received unconditional clearance from the European Commission for the purchase of the Hydro polymers businesses in Norway, Sweden and the UK from Norsk Hydro ASA. The acquisition was agreed with Norsk Hydro last year and includes the remaining 50% interest in the Noretyl ethylene cracker at Rafnes, INEOS Group having acquired the other 50% from Borealis last summer. INEOS expects the acquisition to be completed in the next week.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Great Lakes receives german environment agency approval for phosphorus-bases fluid and lubricant additive - Durad® 310M Approved for Use in Rapidly Biodegradable Hydraulic Fluids and Lubricants
ChemFirst Fully Resumes Aniline Production at Pascagoula - Acquisition by DuPont Expected to be Completed this Week
INEOS Styrenics: Price increase for all PS products in Europe
Terra Industries Inc. Suspends Production at Blytheville facility
Don't Give the Slightest Chance to Toxic Elements in Medicinal Products - New high-accuracy reference solutions for the SI-traceable measurement
Westlake Chemical Joins Global Alliance to End Plastic Waste
SciQuest Releases EMAX Substance Manager Software to Accelerate Drug Discovery for Pharmaceutical and Biotech Industries